SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending as investors debate the potential for a transformative buyout following reports of massive pharmaceutical M&A activity in the oncology space. Community discussions are highly polarized, with bulls highlighting the trial's prolonged survival timeline as evidence of therapeutic success, while bears express concern over the company's financial structure and the potential for a binary clinical outcome.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is generating intense community speculation as investors anticipate imminent Phase 3 VELA data, fueling intense M&A discussions and optimism that sonelokimab will emerge as a best-in-class treatment for hidradenitis suppurativa. The community is closely watching for a potential data release to coincide with upcoming investor presentations, which many believe could trigger a massive rerating event due to the drug's demonstrated efficacy and superior safety profile over existing competition.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is trending as market participants closely monitor geopolitical tensions in the Middle East and their potential impact on energy markets and interest rate sentiment. The community is actively debating the durability of the AI-driven tech rally amidst record market highs and ongoing economic uncertainty.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is witnessing extreme volatility and a parabolic rally, fueled by intense investor enthusiasm surrounding AI-driven memory storage demands and persistent supply chain bottlenecks. The stock has become a primary focal point for momentum traders, sparking heated debates between bulls banking on a structural supercycle and bears warning of a speculative bubble due to its rapid, historic price appreciation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense investor attention following a significant clinical data release for Lupkynis and increased share accumulation by CEO Kevin Tang. While the community is actively debating the potential for an imminent buyout or strategic acquisition, sentiment remains divided between hopeful longs anticipating a catalyst-driven surge and skeptics frustrated by a lack of direct management communication.

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is experiencing significant volatility and social media attention following an announcement regarding a co-development deal with Midjourney, which investors are analyzing as a potential long-term catalyst for the company's semiconductor-based ultrasound technology. While bulls highlight institutional backing and the transformative potential of AI in medical imaging, bears are actively debating the high valuation, persistent cash burn, and the risk of a share offering following the rapid price move.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending following the announcement of a joint research agreement with Honda, which confirms that another major OEM has validated the company's solid-state battery technology after rigorous testing. The community is actively debating the significance of this partnership, weighing the long-term potential of the technology against frustrations over the lack of immediate commercial-scale revenue.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure Corp. is generating significant buzz as investors anticipate potential data center lease announcements and structural growth within the AI infrastructure sector. Community discourse is currently split between bullish sentiment fueled by pipeline progress and institutional interest, and skeptical commentary regarding the firm's lack of signed contracts and current profitability.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Invesco QQQ Trust remains a focal point for investors as the community debates the sustainability of the AI-driven market rally against the backdrop of heightened geopolitical tensions in the Middle East and ongoing trade negotiations. Traders are closely monitoring the interplay between speculative options activity, earnings expectations, and potential shifts in macroeconomic policy.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing heightened volatility as market participants weigh conflicting geopolitical headlines regarding Iran and ongoing negotiations over the Strait of Hormuz. Community sentiment is deeply divided, with traders closely monitoring institutional flows and technical support levels while reacting to the frequent release of market-moving news updates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

CONMED Corporation (NYSE: CNMD) today announced the appointment of John E. Gallagher as Chief Financial Officer (CFO), effective July 15, 2026. Mr. Gallagher succeeds Todd Garner, who remains with the Company in an advisory capacity through November 2, 2026. We are pleased to welcome a talented and...

Here's Why You Should Retain CONMED Stock in Your Portfolio Now

CNMD is sharpening its focus on AirSeal, Buffalo Filter and BioBrace, betting on higher-growth platforms to drive margin gains and long-term growth.

Why Is Conmed (CNMD) Down 3.1% Since Last Earnings Report?

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Can CAH's Surging Other Growth Businesses Become Its Next Profit Engine?

CAH's fast-growing Other Growth Businesses posted 34% revenue growth and 52% profit gains, raising their role in long-term earnings.

CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

CONMED Corporation (NYSE: CNMD) today announced the appointment of Celine Martin and Jeff Mirviss to its Board of Directors (Board), effective July 1, 2026. Ms. Martin will serve as a member of the Audit Committee and the Strategy Committee, and Mr. Mirviss will serve as a member of the...

Is the Options Market Predicting a Spike in CONMED Stock?

Investors need to pay close attention to CNMD stock based on the movements in the options market lately. 

CONMED (NYSE:CNMD) Price Target Lowered to $39.00 at Wells Fargo & Company

Wells Fargo & Company reduced their target price on CONMED from $42.00 to $39.00 and set an "equal weight" rating on the stock in a research note on Friday...

CONMED (NYSE:CNMD) Price Target Lowered to $40.00 at JPMorgan Chase & Co.

JPMorgan Chase & Co. lowered their price target on shares of CONMED from $43.00 to $40.00 and set a "neutral" rating on the stock in a report on Thursday...

CONMED's Q1 Earnings and Revenues Beat, Organic Sales Outlook Up

CNMD tops Q1 estimates despite sales dip, lifts 2026 organic growth outlook as strategic shift sharpens focus on higher-growth segments.

CONMED Q1 Earnings Call Highlights

CONMED (NYSE:CNMD) executives told investors the company is sharpening its focus on higher-growth, higher-margin platforms after reaching agreements to divest its gastroenterology (GI) product lines...

CONMED Corp. is a medical technology company, which engages in providing devices and equipment for surgical procedures. Its products include AirSeal and insufflation, allograft cartilage and tissue, arthroplasty, biliary and endoscopic ultrasound, biomedical sensors and electrodes, biopsy and polypectomy, dilators and accessories, electrosurgical units, fixation devices, hemostasis, implants and suture anchors, infection prevention, patient positioning, and related products. The company was founded by Eugene R. Corasanti in 1970 and is headquartered in Largo, FL.

Conmed Corp.

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.11	--	--	N/A
Q1 '26	$0.82	$0.89	8.72%	BEAT
Q4 '25	$1.32	$1.43	8.01%	BEAT
Q3 '25	$1.05	$1.08	2.86%	BEAT
Q2 '25	$1.12	$1.15	2.37%	BEAT

CNMDConmed Corp.

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CNMD News